The biotech resurrection continues
Positive surprises with Lexicon’s Zynquista and DBV’s Viaskin Peanut show that you can never entirely write biotech off.
Thinking the unthinkable on Covid vaccine approvals
With the EU regulator already reviewing two coronavirus vaccines, could it beat the US FDA to the punch?
Crisis, what crisis? Curevac denies everything
As a Covid-19 vaccine exclusivity and senior management storm engulfs Curevac, the German mRNA specialist insists it’s just conjecture and coincidence.
Internal FDA documents reveal a familiar story for Sarepta
The unexpected approval of Vyondys 53 followed an FDA power struggle, and turned on a vague commitment from Sarepta, it has emerged.
Astra could use a voucher to cement roxadustat’s head start
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
A recap on the past few months of data digging and analysis
Using EvaluatePharma data Vantage explored investment trends in biopharma and medtech, sales per employee at big drug makers, and the declining number of late-stage…
Indivior fights off generic challenges but the threat of litigation remains
Weaker than expected generic erosion of its key Suboxone film product has allowed Indivior to raise full-year guidance.
